Compared implementation of the long-acting buprenorphine treatment buvidal in four European countries.

Background: Buvidal is the only depot buprenorphine currently available in Europe. Buvidal offers a new treatment paradigm, which may require some adjustment in the national regulatory frameworks for opioid agonist treatments (OATs), as well as the national care systems.

Research Design And Methods: Data on the national dissemination of Buvidal, types of populations treated, and the national regulatory framework and care organization system through which Buvidal has been implemented were compared between the UK, Finland, Spain, and France, using a qualitative survey.

Reasons for not entering opioid agonist treatment: A survey among high-risk opioid users in Finland.

To characterise and understand the untreated high-risk opioid user population in Finland, and to determine the reasons why these people do not enter treatment. The study setting was a half-year cross-sectional survey in Finland during 2021-2022. An electronic questionnaire with 24 structured questions was concluded in 16 needle exchange units.